智通财经APP获悉，北海康成-B(01228)再涨超43%，月内累计涨幅已超250%。截至发稿，涨35.38%，报0.44港元，成交额1539.09万港元。
消息面上，北海康成5月底宣布，公司旗下注射用维拉苷酶β(商品名：戈芮宁)获批上市，适用于12岁及以上青少年和成人I型和Ⅲ型戈谢病患者的长期酶替代治疗。值得注意的是，戈芮宁也是北海康成与药明生物在罕见病领域的首个合作项目。
公开资料显示，在戈芮宁获批之前，国内一共有3款获批上市的治疗药物。北海康成创始人、董事长兼首席执行官薛群博士在媒体沟通会上表示，虽然还不能透露具体定价，但可以承诺戈芮宁的上市定价会有大幅下降，对比同类的现有疗法，预计降价至少在50%以上。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.